Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marstacimab prophylaxis in pediatric severe hemophilia
2022-500495-65-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoints: Annualized bleeding rate of treated bleeding events, Adverse events and serious adverse events and 6 more. Planned start Apr 2023; status: authorised.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2022-500495-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500495-65-00.